Replies to post #332070 on Avid Bioservices Inc (CDMO)

[biopharm]

CDMO ($5.31) is trading below our estimate of fair value ($14.3)

Significantly Undervalued: CDMO is trading below fair value by more than 20%.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdmo/avid-bioservices

Looks like new NEW IIS being patient and also looking to buy CDMO

Why would former CEO Steve King being ousted after claiming CDMO contracts bringing Avid to profitability .....then new Avid BOD CEO Rick Hancock speak about the SAME contract that bring Avid to profitability ....

Maybe Merck and their PALL / Danaher ties securing water filtration ...I mean blood filtration also needed to be secured first


________


https://www.biospace.com/article/releases/omeros-discovers-new-cancer-immunity-pathways-controlled-by-gpr174/

Omeros sparking some concerns for Merck as Omeros states "PS Regulates Tumor Immunity"

“Simply put, Omeros has discovered that there are two feet on the cAMP brake pedal restraining immunity against the tumor and, to enable effective tumor-killing activity, both GPR174 and the adenosine pathway must be inhibited. We are optimizing our small-molecule GPR174 inhibitors with the objective of moving orally available therapeutics into the clinic as rapidly as possible. We look forward to providing physicians and patients with a new and broadly applicable option in cancer immunotherapy.”

Omeros is preparing a manuscript for publication detailing its GPR174-related discoveries and data and plans to present these same discoveries and data beginning this year at upcoming oncology international congresses.

_____________

New PS Targeting ...new knowledge coming out constantly...

October 14, 2019

Enhanced computed tomography imaging of breast cancer via phosphatidylserine targeted gold nanoparticles

Needa Alnoor Virani1,
Andria Hendrick2,
Di Wu3,
Benjamin Southard4,
Jael Babb4,
Hong Liu3,
Vibhudutta Awasthi5 and
Roger G Harrison6

Dates

Received 18 April 2019
Revised 3 October 2019
Accepted 14 October 2019
Accepted Manuscript online
14 October 2019

Author affiliations
1 Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, UNITED STATES

2 Pharmaceutical Sciences , University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, UNITED STATES

3 Electrical and Computer Engineering, University of Oklahoma Norman Campus, Norman, Oklahoma, UNITED STATES

4 Chemical, Biological and Materials Engineering, University of Oklahoma Norman Campus, Norman, Oklahoma, UNITED STATES

5 Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, UNITED STATES

6 Chemical, Biological and Materials Engineering and Biomedical Engineering, University of Oklahoma Norman Campus, Norman, Oklahoma, UNITED STATES

Abstract
Breast cancer has one of the highest mortality rates usually due to metastatic development. Mammograms are the current standard of diagnosis; however due to the low sensitivity and high rate of misdiagnosis, patients either experience false positives or negatives leading to overdiagnosis and overtreatment. One of key disadvantages of mammograms is their failed ability to differentiate between a dense breast and a tumor, usually leading to more mammograms and more expensive diagnostic tools. In order to provide a widely available imaging tool, targeted gold nanoparticles have been developed. Gold nanoparticles have been designed with annexin V surface modification to specifically bind phosphatidylserine expressing tumor cells and tumor vasculature. In vitro and in vivo studies showed a significant increase in contrast with targeted nanoparticles. Tumors as small as 4 mm were detectable 4 h post-injection, providing evidence of a promising, sensitive tool for early breast cancer diagnosis.

https://iopscience.iop.org/article/10.1088/2057-1976/ab4d9b